Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2120
Gene Symbol: ETV6
ETV6
0.100 Biomarker phenotype BEFREE <i>ETV6/RUNX1</i> (+) ALL may be heterogeneous in terms of prognosis, and variables such as MRD at end ofremission induction or additional structural abnormalities of 12p could define a subset of patients who are likely to have poor outcome. 27506214 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.010 Biomarker phenotype BEFREE <sup>18</sup>F-FDG PET/CT can be coupled with sensitive bone marrow-based techniques to detect minimal residual disease (MRD) inside and outside the bone marrow, helping to identify those patients who are defined as having imaging MRD negativity. 28368259 2017
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE 50.7% of patients with IGHV-M achieved MRD-negativity posttreatment; of these, PFS was 79.8% at 12.8 years. 26492934 2016
Entrez Id: 102724971
Gene Symbol: LOC102724971
LOC102724971
0.070 Biomarker phenotype BEFREE 50.7% of patients with IGHV-M achieved MRD-negativity posttreatment; of these, PFS was 79.8% at 12.8 years. 26492934 2016
Entrez Id: 102723407
Gene Symbol: LOC102723407
LOC102723407
0.070 Biomarker phenotype BEFREE 50.7% of patients with IGHV-M achieved MRD-negativity posttreatment; of these, PFS was 79.8% at 12.8 years. 26492934 2016
Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
0.060 Biomarker phenotype BEFREE 50.7% of patients with IGHV-M achieved MRD-negativity posttreatment; of these, PFS was 79.8% at 12.8 years. 26492934 2016
Entrez Id: 28309
Gene Symbol: IGHV3OR16-7
IGHV3OR16-7
0.060 Biomarker phenotype BEFREE 50.7% of patients with IGHV-M achieved MRD-negativity posttreatment; of these, PFS was 79.8% at 12.8 years. 26492934 2016
Entrez Id: 2120
Gene Symbol: ETV6
ETV6
0.100 AlteredExpression phenotype BEFREE Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia. 11167743 2000
Entrez Id: 865
Gene Symbol: CBFB
CBFB
0.050 GeneticVariation phenotype BEFREE Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion. 12139724 2002
Entrez Id: 4629
Gene Symbol: MYH11
MYH11
0.100 Biomarker phenotype BEFREE Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion. 12139724 2002
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker phenotype BEFREE Minimal residual disease was assessed by polymerase chain reaction (PCR) for bcl-2/IgH translocations, and chimerism by X,Y-FISH or PCR amplification of short tandem repeat sequences. 12692620 2003
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 GeneticVariation phenotype BEFREE Minimal residual disease (MRD) was investigated in the FLT3/ITD(+) patients using flow cytometry. 12801839 2003
Entrez Id: 25
Gene Symbol: ABL1
ABL1
0.100 Biomarker phenotype BEFREE MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) using probes derived from fusion chimeric genes (BCR/ABL and MLL/AF4) (n=22) or rearrangements of the T-cell receptor or immunoglobulin genes (n=21). 17488684 2007
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.100 Biomarker phenotype BEFREE MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) using probes derived from fusion chimeric genes (BCR/ABL and MLL/AF4) (n=22) or rearrangements of the T-cell receptor or immunoglobulin genes (n=21). 17488684 2007
Entrez Id: 3440
Gene Symbol: IFNA2
IFNA2
0.020 Biomarker phenotype BEFREE Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma. 1932740 1991
Entrez Id: 6962
Gene Symbol: TRBV20OR9-2
TRBV20OR9-2
0.100 Biomarker phenotype BEFREE Minimal residual disease was detected by polymerase chain reaction (PCR) with homo/heteroduplex analysis using consensus primers to IgH and TCR genes. 21774746 2012
Entrez Id: 6343
Gene Symbol: SCT
SCT
0.100 Biomarker phenotype BEFREE MRD negativity predicted lasting remission independent of allo-SCT (N = 7) or non-allo-SCT (N = 9). 22458420 2012
Entrez Id: 2120
Gene Symbol: ETV6
ETV6
0.100 Biomarker phenotype BEFREE MRD status was the strongest predictor of outcome with 5 year EFS rates greater that 90% seen in those patients with low-risk MRD and this was associated with TEL/AML1 rearrangement, high hyperdiploidy (HH) karyotype and female gender. 23242576 2013
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 GeneticVariation phenotype BEFREE MRD status was the strongest predictor of outcome with 5 year EFS rates greater that 90% seen in those patients with low-risk MRD and this was associated with TEL/AML1 rearrangement, high hyperdiploidy (HH) karyotype and female gender. 23242576 2013
Entrez Id: 6962
Gene Symbol: TRBV20OR9-2
TRBV20OR9-2
0.100 GeneticVariation phenotype BEFREE MRD status was assessed in 43 patients by the detection of major rearrangements in TCR and Ig and the presence of chimeric mRNA. 23388549 2013
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 GeneticVariation phenotype BEFREE MRD for the bcl-2/IgH translocation was determined on bone marrow cells in a centralized laboratory belonging to the Euro-MRD consortium, using qualitative and quantitative polymerase chain reactions (PCRs). 24085766 2013
Entrez Id: 4869
Gene Symbol: NPM1
NPM1
0.100 GeneticVariation phenotype BEFREE Minimal residual disease (MRD) was negative in evaluable patients in CR2, particularly in NPM1 mutated cases. 24375467 2014
Entrez Id: 57292
Gene Symbol: KIR2DL5A
KIR2DL5A
0.010 Biomarker phenotype BEFREE MRD-positive patients were more likely to have KIR2DL5A (P = 0.006) and expressed less activating receptor NKp46 and FASL on their NK cells (P = 0.0074 and P = 0.029, respectively). 25281696 2014
Entrez Id: 9437
Gene Symbol: NCR1
NCR1
0.010 AlteredExpression phenotype BEFREE MRD-positive patients were more likely to have KIR2DL5A (P = 0.006) and expressed less activating receptor NKp46 and FASL on their NK cells (P = 0.0074 and P = 0.029, respectively). 25281696 2014
Entrez Id: 4345
Gene Symbol: CD200
CD200
0.010 AlteredExpression phenotype BEFREE MRD analysis during treatment showed stable expression patterns of CD200. 27521317 2016